Medical professional requires transition from favipiravir to simpler molnupiravir

A main well being skilled says Thailand should section out the use of favipiravir, saying molnupiravir is a more effective Covid-19 treatment. Dr Opass Putcharoen, from the Thai Red Cross Emerging Infectious Diseases Clinical Centre, says this shall be essential as the nation strikes to declaring Covid-19 endemic. He added that the worth of molnupiravir produced in India is someplace between 600 and 700 baht per remedy course, in comparison with 50,000 baht for the molnupiravir version produced by Merck.
According to a Bangkok Post report, the Public Health Ministry has previously said that a course of favipiravir costs around 1,000 baht, whereas a molnupiravir treatment course prices 10,000 baht. Earlier this week, Cabinet gave the go-ahead to ditch a procurement plan for 50,000 doses of molnupiravir, in favour of 17 million favipiravir tablets and 5,166 vials of the antiviral medicine, remdesivir.
Replicate points out that while favipiravir has been the primary treatment of choice in Thailand, there is no clear information that proves its efficacy. By contrast, a recent study shows that molnupiravir is 30% efficient at stopping severe sickness in Covid-19 sufferers. The medic is looking on the federal government to import molnupiravir from India and ensure all hospitals have sufficient provides, so it may be administered promptly to those who want it.
He goes on to say that certain classes of Covid-19 patients are still susceptible to severe illness, even if they’re totally vaccinated. These embody individuals on immunosuppressive drugs, who need entry to efficient treatment. He provides that whereas new infections are expected to drop 2 – 3 weeks after the Songkran vacation, the virus nonetheless must be intently monitored..

Leave a Comment